IPO UPDATE: NeuroDerm's CEO felt well-received, but FibroGen soared
This article was originally published in Scrip
The drug developers NeuroDerm and FibroGen launched initial public offerings on 14 November with two very different results, but even though NeuroDerm's IPO priced below a preliminary range and the stock fell in its first day of trading, CEO Oded Lieberman told Scrip that the Israeli company's Parkinson's disease story "resonated well" with investors.
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.